Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
Gossamer Bio, Inc. today announced its financial results for the fourth quarter and year ended December 31, 2023, and provided a business update.
Uncategorized
Provider groups urge HHS, Congress to mitigate damage from Change cyberattack
The American Hospital Association and the American Medical Association pushed the federal government to offer more financial support as the outage limits providers’ ability to receive payment.
Provider groups urge HHS, Congress to mitigate damage from Change cyberattack Read More »
BD starts trial of vascular covered stent in peripheral arterial disease
Peripheral vascular disease is one of six key platforms that BD is targeting for growth.
BD starts trial of vascular covered stent in peripheral arterial disease Read More »
MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
MyMD Pharmaceuticals, Inc. today announced that it received notice from The Nasdaq Stock Market LLC (“Nasdaq”) on March 4, 2024 informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (“Listing Rule”).
Grace Science, LLC Announces First Patient Treated in Phase 1/2/3 Trial of GS-100, an AAV9 Gene Therapy for NGLY1 Deficiency
Grace Science, LLC announced today that the first patient was dosed in an open-label Phase 1/2/3 clinical trial of GS-100, an AAV9 gene replacement therapy for the treatment of NGLY1 Deficiency.
Gilead Sciences CEO on Company’s Evolution and Commitment to the Bay Area
Today the Foster City-based company is the second-largest biotech employer in the Bay Area.
Gilead Sciences CEO on Company’s Evolution and Commitment to the Bay Area Read More »
Twist Bioscience Launches IVDR-compliant Precision Dx Products for Whole Exome Sequencing
Twist Bioscience Corporation today announced European Union (EU) in vitro diagnostic regulations (IVDR) compliant Twist Precision Dx next-generation sequencing (NGS) Products.
Haemonetics Announces Definitive Agreement to Acquire Attune Medical
Haemonetics Corporation announced that it has entered into a definitive agreement to acquire privately-held Chicago-based Attune Medical, the manufacturer of the ensoETM® proactive esophageal cooling device, the only FDA-cleared temperature regulation device indicated for esophageal protection during radiofrequency cardiac ablation procedures.
Haemonetics Announces Definitive Agreement to Acquire Attune Medical Read More »
Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema
Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, announced the data from a successful Phase Ib/IIa trial for lead candidate EXN407.